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Acquired secondary mutations in the anaplastic lymphoma kinase 
(ALK) gene have been identified in ALK-rearranged (ALK+) non–
small-cell lung cancer (NSCLC) patients who developed disease pro-
gression while on crizotinib treatment. Here, we identified a novel 
secondary acquired NSCLC ALK F1174V mutation by comprehensive 
next-generation sequencing in one ALK+ NSCLC patient who pro-
gressed on crizotinib after a prolonged partial response to crizotinib. 
In a second case, we identified a secondary acquired ALK G1202R, 
which also confers resistance to alectinib (CH5424802/RO5424802), 
a second-generation ALK inhibitor that can inhibit ALK gatekeeper 
L1196M mutation in vitro. ALK G1202R is located at the solvent 
front of the ALK kinase domain and exhibits a high level of resistance 
to all other ALK inhibitors currently in clinical development in vitro. 
Comprehensive genomic profiling of resistant tumor is increasingly 
important in tailoring treatment decisions after disease progression on 
crizotinib in ALK+ NSCLC given the promise of second-generation 
ALK inhibitors and other therapeutic strategies.
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Acquired secondary resistance mutations to crizotinib in anaplastic lymphoma kinase (ALK)-rearranged (ALK+) 
non–small-cell lung cancer (NSCLC) has been described.1–4 
In this brief report, we identified a novel acquired secondary 
ALK mutation (ALK F1174V) in an ALK+ NSCLC patient 
who progressed on crizotinib and demonstrated that a previ-
ously described secondary mutation, ALK G1202R, confers 
high level of intrinsic resistance to alectinib, a more potent 
ALK inhibitor in clinical development, validating in vitro data 
in a patient for the first time.2
Case 1 is a 61-year-old Asian man never-smoker who 
was diagnosed with stage IV NSCLC in October 2010. 
Patient was initially treated empirically with erlotinib but 
had disease progression and received six cycles of carbo-
platin/pemetrexed/bevacizumab followed by pemetrexed 
maintenance. Fluorescence in situ hybridization assayed 
performed was part of screening for a clinical trial of crizo-
tinib was positive for the presence of ALK rearrangement 
but negative for ROS1 rearrangement or MET amplification. 
Patient was enrolled onto a single-arm phase 2 crizotinib trial 
(NCT00932451) in May 2011. Repeat magnetic resonance 
imaging of the brain revealed no brain metastasis at the time 
of enrollment. He achieved a confirmed partial response after 
3 months on crizotinib that lasted 21 months (Fig. 1A). A new 
1.8 cm right upper lobe (RUL) pleural nodule that was fluo-
rodeoxyglucose (FDG)-avid was detected in February 2013 
(Fig. 1B). The patient continued on crizotinib for ongoing 
clinical benefit as he remained asymptomatic. Over the next 6 
months, the RUL lobe lesion continued to grow with appear-
ance of a new  FDG-avid right lower lobe nodule (Fig. 1C). 
Computed tomography–guided biopsy of the dominant RUL 
nodule revealed adenosquamous histology (Fig. 2). Formalin-
fixed,  paraffin-embedded tissue was submitted to a Clinical 
Laboratory Improvement Amendments–certified, College of 
American Pathologist–accredited laboratory, where hybrid-
ization capture of 3769 exons of 236 cancer-related genes 
and 47 introns of 19 genes frequently rearranged in cancer 
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was applied to 200 ng of DNA extracted from this sample and 
sequenced to high, uniform coverage of 939x (Foundation 
One, Foundation Medicine Inc., Cambridge, MA). This assay 
confirmed the presence of EML4-ALK variant 3 (E6; A20) 
and identified the presence of a novel ALK F1174V mutation 
(Fig. 3A) and quantitatively estimated the ALK F1174V allele 
frequency at 23% in a background of 40% tumor purity, con-
sistent with a clonal heterozygous substitution; a S45 deletion 
in CTNNB1 was also detected. The patient is now enrolled 
in a phase 2 trial of alectinib (RO5424802/CH5424802) for 
crizotinib-resistant ALK+ NSCLC patients (NCT01588028) 
at 600 mg orally twice a day (the recommended phase 2 dose).
Case 2 is a 60-year-old Asian woman never-smoker 
who was diagnosed with stage IV adenocarcinoma of the 
lung NSCLC in June 2010. She received four cycles of car-
boplatin/albumin bound-paclitaxel/bevacizumab chemo-
therapy followed by pemetrexed/bevacizumab maintenance 
chemotherapy from July 2010 to December 2010 but had 
disease progression in January 2011. Fluorescence in situ 
hybridization assay on her tumor was positive for ALK rear-
rangement and negative for ROS1 rearrangement or MET 
amplification. She was enrolled on a single-arm phase 2 crizo-
tinib trial (NCT00585195) in February 2011 and achieved a 
confirmed partial response after 3 months of crizotinib treat-
ment (RECIST 1.0)5 (Fig. 2A and B). Twenty months into 
crizotinib treatment, she developed RECIST-defined disease 
progression of 20% increase in aggregate tumor measure-
ment from the lowest achieved baseline achieved due to an 
enlarging right hilar lymph node. Simultaneously, a right 
axillary lymph node demonstrated increasing FDG avidity 
with a standardized uptake value (SUV) of 2.0 (Figs. 1C and 
2A) but was still normal in size (<1 cm). She was continued 
on crizotinib post progression due to ongoing clinical ben-
efit as she was asymptomatic and her aggregate tumor mea-
surement was still at 63% reduction from the precrizotinib 
treatment level. The right axillary lymph node (LN) contin-
ued to grow in size to 1.1 cm and the SUV increased to 7.8 
(Fig. 2D). Crizotinib was discontinued and patient was 
FIGURE 1. A, Partial response to crizotinib 12 months after crizotinib treatment. B, Appearance of a new right upper lobe 
pleural-based nodule after 26 months of crizotinib treatment. C, Continual growth of the right upper lobe pleural-based nodule 
and a new right lower lobe nodule after 32 months of crizotinib treatment.
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enrolled onto the same alectinib trial as patient 1. Pre-
enrollment the right axillary LN measured 1.5 cm with a SUV 
of 8.9 (Fig. 2E). Restaging workup did not reveal any brain 
metastasis. She started alectinib 600 mg orally twice a day 
on May 2013. Nevertheless, disease progression continued 
after 5 weeks on alectinib, as evidence the right axillary LN 
had increased in size to 2.0 cm with a SUV of 11.9 (Fig. 2F). 
RECIST progression was confirmed 9 weeks (Fig. 2G) after 
starting alectinib due to continued growth of the right axillary 
LN to 2.2 cm with a SUV of 11.0. Patient also had pain around 
the right axillary lymph node, which was completely excised 
for symptoms relief. Fifteen 4-μm-thick unstained slides from 
the  formalin-fixed paraffin-embedded lymph node were run 
on the Foundation One test. The assay confirmed the presence 
of an EML4-ALK rearrangement (E6; A20) (variant 3) and an 
ALK G1202R mutation with an estimated allele frequency of 
23% in a background of 60% tumor purity, consistent with a 
near clonal heterozygous substitution (Fig. 3B). In addition, 
loss of CDKN2A/B and ARFRP1 amplification (9X) were 
identified. No EGFR or KRAS alterations or ALK amplifica-
tion was identified. The patient’s original tumor tissue was 
exhausted during the Lung Cancer Mutation Consortium 
profiling effort. Patient’s right chest pain was resolved post 
axillary lymph node excision and continued on alectinib post 
progression as allowed by protocol but had continued disease 
progression (Fig. 2H). Of note, both patients’ tumor sample 
was profiled using the SNaPSHOT analysis6 of 15 genes (APC, 
AKT1, BRAF, CTNNB1, EGFR, FLT3, JAK2, KRAS, MEK1, 
NOTCH1, NRAS, PIK3CA, PTEN, TP53) and was negative 
for base substitutions at mutational “hotspots”; notably, ALK 
sequencing is not a component of this analysis.
DISCUSSION
To date, the major mechanisms of crizotinib resistance 
in ALK+ NSCLC patients include acquired secondary resis-
tance mutations in the kinase domain,1–4 amplification of the 
ALK fusion gene,7 and bypass track activation.3,4 Using a tar-
geted comprehensive next-generation sequencing approach, 
we have identified a novel ALK F1174V mutation in an ALK+ 
NSCLC patient resistant to crizotinib. Previously, an ALK 
F1174L mutation has been identified as an acquired second-
ary resistance mechanism to crizotinib in an inflammatory 
myofibroblastic tumor patient harboring RANBP2-ALK rear-
rangement who progressed on crizotinib.8 ALK F1174L is also 
a common activating mutation in sporadic neuroblastoma, 
but rare base substitutions in the other two codons encoding 
FIGURE 2. A, FDG PET scan of patient before start-
ing crizotinib treatment. B, FDG PET scan of patient 
after 3 months of crizotinib treatment. C, FDG PET 
scan of patient after 20 months of crizotinib treat-
ment. D, FDG PET scan of patient after 23 months 
of crizotinib treatment. E, FDG PET scan of patient 
after 26 months of crizotinib treatment and 4 weeks 
before starting alectinib treatment. F, FDG PET 
scan of patient after 5 weeks of alectinib treatment. 
G, FDG PET scan of patient after 9 weeks of alec-
tinib treatment. H, FDG PET scan of patients after 
excision of right axillary lymph nodes and after 12 
weeks of alectinib treatment, which showed contin-
ued disease progression in the thorax. FDG, fluoro-
deoxyglucose; PET, positron emission tomography.
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phenylalanine at residue 1174 (F1174V, F1174C) have been 
also been reported in neuroblastoma.9 In vitro chemical muta-
genesis experiments in the setting of increasing crizotinib 
dose have identified phenylalanine at amino acid residue 
1174 as a common site of secondary resistance to crizotinib 
and involving all three positions of the codon encoding phe-
nylalanine (F1174L/C/V/I).10 Earlier to this report, there are 
no reports identifying base substitutions within the codon 
of phenylalanine at amino acid residue 1174 as a secondary 
acquired crizotinib resistance mechanism in NSCLC. The 
RANBP2-ALK F1174L mutation lies near the C-terminus of 
the αC helix, and its side chain is involved in the hydropho-
bic core adjacent to the activation loop of the ALK protein. 
The leucine (L) for phenylalanine (F) alteration is thought to 
reduce the side chain size which weakens the normal autoin-
hibitory interactions thereby allowing ALK F1174L to favor 
the active conformation11 thereby increasing the ATP-binding 
affinity of ALK and basal activation of ALK8,11,12 without 
increasing its affinity for crizotinib, with a net effect of reduc-
ing crizotinib sensitivity. As both valine (V) and leucine (L) 
are branched chain hydrophobic amino acids, we hypothesize 
that the resistance mechanism of ALK F1174V is similar to 
ALK F1174L. Indeed, neuroblastoma cell lines harboring the 
ALK F1174V mutation (CHLA90, CLB-GE) ALK kinase 
activity are increased.13,14 In vitro cell-based experiments 
have shown that ALK inhibitors with higher affinity for the 
ALK kinase domain (alectinib, LDK378, AP26113) can over-
come the ATP-binding kinetics of ALK F1174L.15 In contrast, 
FIGURE 3. A, Schematic represen-
tation of the base substitution result-
ing in a codon alteration and amino 
acid changed at position 1174. B, 
Schematic representation of the base 
substitution resulting in a codon 
alteration and amino acid changed 
at position 1202.
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ALK G1202R, which has been previously described in a 
patient who progressed on crizotinib,2 is highly resistant to all 
ALK inhibitors in clinical development (LDK378, alectinib, 
ASP3026, AP26113)2,15 although the PK level achieved at the 
recommended dose of AP26113 (180 mg qD) is above the 
concentration needed to inhibit 50% of (IC
50
) ALK G1202R.15 
ALK G1202R is postulated to be on the solvent-exposed 
region of the ALK kinase domain abutting the crizotinib-bind-
ing site and likely diminishes the binding affinity of crizo-
tinib and other ALK inhibitors to the mutant ALK from steric 
hindrance due to the presence of a large basic residue.2 We 
are not certain whether the G1202R mutation arose following 
crizotinib resistance or alectinib therapy, although the timing 
of disease progression on alectinib suggests that it was present 
at the time of crizotinib resistance.
It is unknown the significance of role of S45 dele-
tion in the CTNNB1 in the background of ALK F1174V or 
loss of CDKN2A/B and ARFRP1 amplification in the back-
ground of ALK G1202R in conferring resistance to crizotinib. 
Nevertheless, targeted next-generation sequencing offers 
comprehensive genomic profiling allowing the identification 
of population of resistant tumor clones and other underlying 
genetic alterations beyond secondary acquired mutations thus 
offering increased granularity in one diagnostic setting allow-
ing even the small amount of tumor obtained from rebiopsy to 
yield significant useful clinical information.
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